The expansion covers the full blood pressure spectrum, from pre-hypertension to Stage 2, allowing for earlier clinical intervention. For DarioHealth, the deal is a significant win for its land-and-expand strategy. By integrating cardiometabolic care into the existing contract, the company estimates the revenue opportunity within this specific customer relationship could triple.

Revenue from the expanded program is slated to begin in 2026, with a more substantial financial impact anticipated in 2027. CEO Erez Raphael stated that the growth validates the company’s focus on delivering measurable outcomes across multiple chronic conditions. Currently, DarioHealth serves 12 health plan customers, including three national carriers, as payers increasingly demand unified platforms that address high-cost chronic issues rather than fragmented, episodic care.